27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Alzheimer's disease is a neurodegenerative disorder affecting millions globally, with early detection being critical for effective management. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Early detection of Alzheimer's disease is crucial for effective treatment, and the use of brain MRI images has become a common method for diagnosis. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The Early Stages of Alzheimer’s Detection project focuses on identifying signs of Alzheimer’s disease at the earliest possible stage using advanced machine learning and medical imaging techniques. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The Early Stages of Alzheimer’s Detection project focuses on identifying signs of Alzheimer’s disease at the earliest possible stage using advanced machine learning and medical imaging techniques. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's Disease acts as a degenerative brain trauma that results in poor memory, alongside impairing mental functioning. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease is a form of progressive dementia that significantly impacts the quality of life of patients and their families. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study proposes a deep learning-based framework to detect and classify Alzheimer's disease (AD) in the early stages using medical imaging, and specifically Magnetic Resonance Imaging (MRI). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer disease represents a major medical and social challenge owning to the complexity of its diagnosis, especially at the preclinical stage. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In recent years, it has been possible for patients with Down syndrome to live longer with advanced medical treatment and social support. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The accurate diagnosis tends to remain critical for the improvement of the patient outcomes in the Alzheimer’s disease (AD), where a progressive neurodegenerative disorder with the growing of the global impact. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Penyakit Alzheimer adalah jenis demensia akibat kerusakan pada neuron otak yang memengaruhi memori, bahasa, dan berpikir. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This survey presents 50 research papers focussed on various techniques in Alzheimer classification techniques using 3D MRI images, and the categorisation of the techniques is made based on the fusion-based, convolutional neural network (CNN)-based, random forest (RF)-based and support vector machine (SVM)-based approaches. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
OASIS-3 is a compilation of MRI and PET imaging and related clinical data for 1098 participants who were collected across several ongoing studies in the Washington University Knight Alzheimer Disease Research Center over the course of 15 years. 4 key findings →
Design: longitudinal study Participants: 1,098 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Adults with Down syndrome carry high risk of developing Alzheimer’s disease and efforts to include this population in clinical trials remain limited. 4 key findings →
Design: longitudinal study Participants: 237 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Adults with Down syndrome (DS) are at risk for Alzheimer’s disease (AD). 4 key findings →
Design: cohort study Participants: 167 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The integration of artificial intelligence in medical image classification has significantly advanced disease detection. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cognitively normal older adults are often regarded as a homogeneous population in preventive and disease-modifying clinical trials for dementia. 2 key findings →
Design: prospective cohort Participants: 1,136 Evidence: moderate
Full summary, score breakdown and related studies → Original source
BACKGROUNDQuantitative amyloid-beta (A{beta})-PET is increasingly used in AD prevention trials. 3 key findings →
Design: longitudinal study Participants: 433 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Cerebral small vessel disease (cSVD) is a leading cause of stroke and dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BackgroundThe brain age gap (BAG), the difference between neuroimaging-predicted and chronological age, captures inter-individual variation in brain aging. 2 key findings →
Design: longitudinal study Participants: 202 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
INTRODUCTIONNeurodegenerative research identifies biomarkers to confirm presence of disease and inform about risk for clinical symptoms. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BackgroundUp to 30% of individuals harboring core Alzheimers disease (AD) neuropathology--amyloid-{beta} (A{beta};A) and tau (T)--remain cognitively unimpaired. 1 key finding →
Design: cohort study Participants: 500 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
BackgroundThe Centiloid (CL) scale standardizes global amyloid PET quantification and is widely used to define amyloid positivity. 5 key findings →
Design: meta-analysis Participants: 71 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The purpose of this meta-analysis was to determine the common signature of dysregulated brain glucose metabolism in late-onset age-associated neurodegenerative diseases (A2NDs), including Alzheimer disease, Parkinson disease, and amyotrophic lateral sclerosis. 2 key findings →
Design: meta-analysis Participants: 5,298 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
10 of the 2,885 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →